HTD 1801

Drug Profile

HTD 1801

Latest Information Update: 12 Jan 2017

Price : $50

At a glance

  • Originator HighTide Biopharma
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Primary sclerosing cholangitis

Most Recent Events

  • 09 Jan 2017 Preclinical trials in Primary sclerosing cholangitis in Australia prior to January 2017 (PO) (ACTRN12617000031369p)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top